V Square Quantitative Management LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,872 shares of the company’s stock after buying an additional 59 shares during the period. V Square Quantitative Management LLC’s holdings in IDEXX Laboratories were worth $912,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Riverview Trust Co purchased a new position in IDEXX Laboratories in the first quarter valued at approximately $26,000. Crewe Advisors LLC acquired a new position in IDEXX Laboratories during the first quarter worth $26,000. Institutional & Family Asset Management LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth $28,000. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth about $33,000. Finally, Private Wealth Management Group LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Down 2.6 %
Shares of NASDAQ IDXX traded down $12.60 during mid-day trading on Wednesday, reaching $475.22. The company had a trading volume of 286,032 shares, compared to its average volume of 489,530. The stock’s 50 day moving average is $485.53 and its 200-day moving average is $512.33. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The stock has a market capitalization of $39.25 billion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 3.91 and a beta of 1.32.
Insider Activity at IDEXX Laboratories
In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.11% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on IDXX. Barclays reduced their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Piper Sandler reduced their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Finally, Morgan Stanley reduced their price objective on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $582.25.
Check Out Our Latest Stock Analysis on IDXX
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- How to Calculate Return on Investment (ROI)
- Brinker International’s Price Dip is an Appetizing Entry Point
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Stocks That Could Beat the September Blues
- How to Invest in Blue Chip Stocks
- Canopy Growth Stock: Can It Sustain Recent Gains?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.